|
Screening, vaccine and cost parameters |
|||
| Parameters |
Base case |
Ranges |
References |
|
|
|||
| Screening characteristics |
|||
| Screening interval |
3 years in ages 25–49 years and 5 years in ages 50–64 years |
NHS cervical screening programme 22 |
|
| Coverage rates of target groups by age (2003) |
|||
| 25–29 |
74.0% |
NHS cervical screening programme 22 |
|
| 30–34 |
81.0% |
||
| 35–39 |
83.7% |
||
| 40–44 |
84.0% |
||
| 45–49 |
83.8% |
||
| 50–54 |
83.2% |
||
| 55–59 |
81.4% |
||
| 60–64 |
77.3% |
||
| Inadequate pap smear results |
10% |
5% – 20% |
|
| Pap Sensitivity for CIN 1/2 Pap sensitivity for CIN 1/2 (LBC) |
61% |
51% – 80% |
Nanda et al23and Karnon et al25 |
| Pap Sensitivity for CIN 3 Pap Sensitivity for CIN 3 (LBC) |
65% |
65% – 90% |
Nanda et al23 and Karnon et al25 |
| Pap Specificity for no CIN Pap Specificity for no CIN (LBC) |
95.7% |
90% – 99% |
Nanda et al25 and Kulasingam et al24 |
| Colposcopy/Biopsy Sensitivity |
90% |
88% – 100% |
Mitchell et al27 |
| Colposcopy/Biopsy Specificity |
100% |
65% – 100% |
Kulasingam et al24 and Karnon et al25 |
| Vaccine characteristics |
|||
| Vaccine efficacy for all 6, 11, 16, 18 HPV types |
98% |
85% – 100% |
Villa et al5 and Future II 6 |
| Duration of efficacy |
Lifetime |
From 10 years to lifetime |
Olsson et al 28 and Villa et al42 |
| Vaccine coverage |
85% |
50%–90% |
Trotter et al31 and Bramley et al32 |
| Booster coverage |
50% |
Trotter et al31 |
|
| Costs |
|||
| Pap smear |
£23.7 |
£18 – £30 |
Brown et al 26 Curtis et al38 |
| Colposcopy (with or without biopsy) |
£141.69 |
£113 – £170 |
|
| Knife cone biopsy of cervix uteri |
£290.64 |
£232 – £349 |
|
| CIN 1, CIN 2, CIN 3 |
£313.14 |
£250 – £376 |
|
| FIGO I |
£12,142 |
£9,714 – £14,570 |
Curtis et al38 and Wolstenholme et al37 |
| FIGO II |
£22,061 |
£17,649 – £26,473 |
|
| FIGO III |
£21,785 |
£17,428 – £26,142 |
|
| FIGO IV |
£23,402 |
£18,722 – £28,082 |
|
| Genital warts |
£215.73 |
£172 – £259 |
Brown et al26 and Curtis et al38 |
| Vaccine cost/dose |
£75 |
£70 – £80 |
|
| Administration cost/dose |
£ 3.4 |
£0 – £12 |
Trotter et al31 |
| Booster cost/dose |
£75 |
||
| Administration cost for booster |
£10 |
Curtis et al38 |
|
| Discount rates |
|||
| Costs |
3.5% |
0 – 5% |
|
| Benefits |
3.5% |
0 – 5% |
|
Kulasingam et al. Cost Effectiveness and Resource Allocation 2008 6:4 doi:10.1186/1478-7547-6-4 |
|||